Moderna Cancer Vaccine With Merck's Keytruda Delays Return Of Deadly Skin Cancer

An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S.